Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - oxaliplatin 50mg;   - powder for injection - 50 mg - active: oxaliplatin 50mg   excipient: lactose

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

wockhardt bio pty ltd - oxaliplatin, quantity: 100 mg - injection, concentrated - excipient ingredients: nitrogen; water for injections - oxaliplatin is indicated for adjuvant treatment of stage iii (duke?s c) colon cancer, in combination with fluoropyrimidine agent.,oxaliplatin in combination with fluorouracil and folinic acid is indicated for the treatment of advanced colorectal cancer.,oxaliplatin in combination with capecitabine, with or without bevacizumab, is indicated for the treatment of patients with metastatic colorectal cancer,oxaliplatin in combination with epirubicin and either capecitabine or fluorouracil, is indicated for the treatment of patients with advanced oesophagogastric cancer.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

wockhardt bio pty ltd - oxaliplatin, quantity: 50 mg - injection, concentrated - excipient ingredients: nitrogen; water for injections - oxaliplatin is indicated for adjuvant treatment of stage iii (duke?s c) colon cancer, in combination with fluoropyrimidine agent.,oxaliplatin in combination with fluorouracil and folinic acid is indicated for the treatment of advanced colorectal cancer.,oxaliplatin in combination with capecitabine, with or without bevacizumab, is indicated for the treatment of patients with metastatic colorectal cancer,oxaliplatin in combination with epirubicin and either capecitabine or fluorouracil, is indicated for the treatment of patients with advanced oesophagogastric cancer.

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - oxaliplatin 50mg - powder for injection - 50 mg - active: oxaliplatin 50mg excipient: lactose - oxaliplatin, in combination with 5-fluorouracil and folinic acid, is indicated for: · adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour.

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - oxaliplatin 50mg;   - powder for infusion - 50 mg - active: oxaliplatin 50mg   excipient: lactose - oxaliplatin, in combination with fluorouracil and folinic acid, is indicated for adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour;

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

wockhardt bio pty ltd - oxaliplatin, quantity: 100 mg - injection, concentrated - excipient ingredients: water for injections; nitrogen - oxaliplatin is indicated for adjuvant treatment of stage iii (duke?s c) colon cancer, in combination with fluoropyrimidine agent.,oxaliplatin in combination with fluorouracil and folinic acid is indicated for the treatment of advanced colorectal cancer.,oxaliplatin in combination with capecitabine, with or without bevacizumab, is indicated for the treatment of patients with metastatic colorectal cancer,oxaliplatin in combination with epirubicin and either capecitabine or fluorouracil, is indicated for the treatment of patients with advanced oesophagogastric cancer.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

wockhardt bio pty ltd - oxaliplatin, quantity: 50 mg - injection, concentrated - excipient ingredients: nitrogen; water for injections - oxaliplatin is indicated for adjuvant treatment of stage iii (duke?s c) colon cancer, in combination with fluoropyrimidine agent.,oxaliplatin in combination with fluorouracil and folinic acid is indicated for the treatment of advanced colorectal cancer.,oxaliplatin in combination with capecitabine, with or without bevacizumab, is indicated for the treatment of patients with metastatic colorectal cancer,oxaliplatin in combination with epirubicin and either capecitabine or fluorouracil, is indicated for the treatment of patients with advanced oesophagogastric cancer.

Israel - inglês - Ministry of Health

tzamal bio-pharma ltd - oxaliplatin - powder for solution for infusion - oxaliplatin 50 mg/vial - oxaliplatin - oxaliplatin - oxaliplatin in combination with 5-fluorouracil (5-fu) and folinic acid (fa) is indicated for: • adjuvant treatment of stage iii (duke‘s c) colon cancer after complete resection of primary tumor. • treatment of metastatic colorectal cancer. oxaliplatin in combination with leucovorin, irinotecan and 5-fluorouracil is indicated for the first-line treatment of patients with metastatic pancreatic adenocarcinoma (based on nccn guidelines, version 2.2014).

Israel - inglês - Ministry of Health

tzamal bio-pharma ltd - oxaliplatin - powder for solution for infusion - oxaliplatin 150 mg/vial - oxaliplatin - oxaliplatin - oxaliplatin in combination with 5-fluorouracil (5-fu) and folinic acid (fa) is indicated for: • adjuvant treatment of stage iii (duke‘s c) colon cancer after complete resection of primary tumor. • treatment of metastatic colorectal cancer. oxaliplatin in combination with leucovorin, irinotecan and 5-fluorouracil is indicated for the first-line treatment of patients with metastatic pancreatic adenocarcinoma (based on nccn guidelines, version 2.2014).

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - oxaliplatin, quantity: 50 mg - injection, solution - excipient ingredients: lactose monohydrate; water for injections - oxaliplatin, in combination with fluorouracil and folinic acid, is indicated for: - adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour; - treatment of advanced colorectal cancer